Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This drug is a **combination vaccine regimen** consisting of an inactivated hepatitis A vaccine administered together with measles, mumps, and rubella (MMR) vaccine. The hepatitis A vaccine contains inactivated hepatitis A virus antigen, which stimulates an immune response providing protection against hepatitis A[1][3]. The MMR vaccine includes live attenuated strains of measles, mumps, and rubella viruses that induce protective immunity against the three diseases[2][3]. The combination regimen is typically administered to children aged 12 to 23 months and shown to be non-inferior in immunogenicity and safety compared to administration of each vaccine separately[1][3]. This approach is used to optimize the pediatric immunization schedule by providing protection against multiple diseases in a single visit[1][3]. Both vaccine components work through **active immunization** by stimulating adaptive immune responses through antigen presentation. The hepatitis A component is inactivated, while the MMR component is live attenuated[1][3]. Primary indications are prevention of hepatitis A, measles, mumps, and rubella in children.
- Other names
- inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine
02
Targets
Hepatitis A virus capsid proteinMV (Measles virus)Mumps virus antigen
Beyond the preview
Go deeper on inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated hepatitis A vaccine + measles, mumps, and rubella vaccine.